Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | DHODH | Q02127 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3332556 | 0.91 | ALDH1A1 (0.34) | KMT2AALDH1A1MEN1NPSR1MAPT | |
| SCHEMBL29356089 | 0.88 | MAOB (0.40) | KMT2AALDH1A1MEN1NPSR1MAPT | |
| SCHEMBL2347918 | 0.88 | MAOB (0.40) | KMT2AALDH1A1MEN1NPSR1MAPT | |
| SCHEMBL2354401 | 0.84 | MEN1 (0.35) | KMT2AMEN1TP53SMN1; SMN2 | |
| SCHEMBL1873945 | 0.83 | KMT2A (0.34) | KMT2AALDH1A1MEN1MAPTLMNA | |
| SCHEMBL1869939 | 0.83 | RAB9A (0.36) | KMT2AALDH1A1MEN1MAPTTP53 | |
| SCHEMBL3334324 | 0.82 | DHODH (0.37) | DHODHMAOB | |
| SCHEMBL3622023 | 0.81 | KDR (0.35) | MAPK14 | |
| SCHEMBL14962991 | 0.80 | MAOB (0.40) | KMT2AALDH1A1MEN1NPSR1MAPT | |
| SCHEMBL3333863 | 0.80 | IKBKB (0.38) | KMT2AALDH1A1NPSR1DHODHSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144674-A1 | PYRIDAZINE DERIVATIVES | SYNGENTA CROP PROTECTION, INC. (US) | 2010-06-10 | — | — | US | claimed |
| EP-2077997-A1 | PYRIDAZINE DERIVATIVES | Syngeta Participations AG (CH) | 2009-07-15 | — | — | EP | claimed |
| WO-2008049585-A1 | PYRIDAZINE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2008-05-02 | — | — | WO | claimed |
| EP-1916240-A1 | Pyridazine derivatives | Syngeta Participations AG (CH) | 2008-04-30 | — | — | EP | claimed |
| US-20100144674-A1 | PYRIDAZINE DERIVATIVES | SYNGENTA CROP PROTECTION, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| EP-2077997-A1 | PYRIDAZINE DERIVATIVES | Syngeta Participations AG (CH) | 2009-07-15 | — | — | EP | disclosed |
| WO-2008049585-A1 | PYRIDAZINE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2008-05-02 | — | — | WO | disclosed |
| EP-1916240-A1 | Pyridazine derivatives | Syngeta Participations AG (CH) | 2008-04-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144674-A1 | PYRIDAZINE DERIVATIVES | C3AR1, C1S, CBR3 | KMT2A 3327/4885ALDH1A1 1874/4885MEN1 4260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.